Special suppressive role of miR-29b in HER2-positive breast cancer cells by targeting Stat3

American Journal of Translational Research

Volumn 7, Issue 5, 2015, Pages 878-890

  Qin, Ling ^a   Li, Rong ^b   Zhang, Junyi ^a   Li, Aimin ^a   Luo, Rongcheng ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b FIRST MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; HER2; miR 29b; Stat3 signaling pathway

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA 29B; STAT3 PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE; CELL INVASION; CELL INVASION ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN ISOLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; WESTERN BLOTTING;

EID: 84936776123     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. [1] DeSantis C, Ma J, Bryan L and Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64: 52-62.
2. [2] Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Au-clair D, Bautista-Pina V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, Thompson KM, Uribe-Figueroa L, Baselga J, Beroukhim R, Polyak K, Sgroi DC, Richardson AL, Jimenez-Sanchez G, Lander ES, Gabriel SB, Garraway LA, Golub TR, Melendez-Zajgla J, Toker A, Getz G, Hidalgo-Miranda A and Meyerson M. Sequence analysis of mutations and transloca-tions across breast cancer subtypes. Nature 2012; 486: 405-409.
3. [3] Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albert-son DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A and Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527.
4. [4] Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
5. [5] Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A and Nevins JR. A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A 2010; 107: 6994-6999.
6. [6] Behm-Ansmant I, Rehwinkel J and Izaurralde E. MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Biol 2006; 71: 523-530.
7. [7] Winter J, Jung S, Keller S, Gregory RI and Died-erichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11: 228-234.
8. [8] O’Day E and Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 2010; 12: 201.
9. [9] Zhang H, Li Y and Lai M. The microRNA network and tumor metastasis. Oncogene 2010; 29: 937-948.
10. [10] Krol J, Loedige I and Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597-610.
11. [11] Farazi TA, Spitzer JI, Morozov P and Tuschl T. miRNAs in human cancer. J Pathol 2011; 223: 102-115.
12. [12] Croce CM. Causes and consequences of mi-croRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-714.
13. [13] Wang Y and Lee CG. MicroRNA and cancer--fo-cus on apoptosis. J Cell Mol Med 2009; 13: 12-23.
14. [14] Sharma S, Kelly TK and Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31: 27-36.
15. [15] Schmitt MJ, Margue C, Behrmann I and Kreis S. MiRNA-29: a microRNA family with tumor-suppressing and immune-modulating properties. Curr Mol Med 2013; 13: 572-585.
16. [16] Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH and Zhuang SM. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51: 836-845.
17. [17] Kriegel AJ, Liu Y, Fang Y, Ding X and Liang M. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 2012; 44: 237-244.
18. [18] Chou J, Lin JH, Brenot A, Kim JW, Provot S and Werb Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol 2013; 15: 201-213.
19. [19] Lang N, Liu M, Tang QL, Chen X, Liu Z and Bi F. Effects of microRNA-29 family members on proliferation and invasion of gastric cancer cell lines. Chin J Cancer 2010; 29: 603-610.
20. 20[] Fang JH, Zhou HC, Zeng C, Yang J, Liu Y, Huang X, Zhang JP, Guan XY and Zhuang SM. MicroR-NA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix me-talloproteinase 2 expression. Hepatology 2011; 54: 1729-1740.
21. [21] Wang C, Bian Z, Wei D and Zhang JG. miR-29b regulates migration of human breast cancer cells. Mol Cell Biochem 2011; 352: 197-207.
22. [22] Sandhu R, Rivenbark AG, Mackler RM, Livasy CA and Coleman WB. Dysregulation of microR-NA expression drives aberrant DNA hypermeth-ylation in basal-like breast cancer. Int J Oncol 2014; 44: 563-572.
23. [23] Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N and Russo A. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 2003; 197: 157-168.
24. [24] Yang Z, Cai JH, Xie SJ, Li GX, Song WQ, Yan QH, Yan L and Zhang F. Therapeutic effects of signal transducer and activator of transcription 3 siRNA on human breast cancer in xenograft mice. Chin Med J (Engl) 2011; 124: 1854-1861.
25. [25] Spitale A, Mazzola P, Soldini D, Mazzucchelli L and Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 2009; 20: 628-635.
26. [26] Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
27. [27] Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
28. [28] Bowman T, Garcia R, Turkson J and Jove R. STATs in oncogenesis. Oncogene 2000; 19: 2474-2488.
29. [29] Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cuf S, Del Barco S, Lopez-Bonet E, Brunet J and Menendez JA. Dynamic emergence of the mesenchymal CD44(pos) CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem Biophys Res Commun 2010; 397: 27-33.
30. [30] Chung SS, Giehl N, Wu Y and Vadgama JV. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchy-mal transition and cancer stem cell traits. Int J Oncol 2014; 44: 403-411.
31. [31] Qian L, Chen L, Shi M, Yu M, Jin B, Hu M, Xia Q, Zhang X, Shen B and Guo N. A novel cis-acting element in Her2 promoter regulated by Stat3 in mammary cancer cells. Biochem Biophys Res Commun 2006; 345: 660-668.
32. [32] Zhang W, Ding W, Chen Y, Feng M, Ouyang Y, Yu Y and He Z. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochim Biophys Sin (Shanghai) 2011; 43: 647-653.
33. [33] Siddiqa A, Long LM, Li L, Marciniak RA and Ka-zhdan I. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer 2008; 8: 129.
34. [34] Harbeck N, Pegram MD, Ruschoff J and Mobus V. Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene. Breast Care (Basel) 2010; 5: 3-7.